OncoMed Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
Published: Nov 12, 2013
REDWOOD CITY, Calif., Nov. 12, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today reported financial results and recent corporate events for the quarter ended September 30, 2013. For the third quarter of 2013, OncoMed reported total revenue of $12.9 million and a net loss of $3.5 million, or $0.15 per share. As of September 30, 2013, OncoMed's cash, cash equivalents and marketable securities totaled $128.6 million.
Help employers find you! Check out all the jobs and post your resume.